MS campaigners seek drug re-think
Friday 05 August 2011
Health campaigners have expressed disappointment after the medicines watchdog rejected the first pill to treat multiple sclerosis.
The MS Society urged the National Institute for Health and Clinical Excellence (Nice) and drug firm Novartis to work together so Gilenya (also called fingolimod) can be re-appraised.
In draft guidance which is subject to consultation, Nice rejected the drug due to "uncertainties" over its effectiveness, a lack of appropriate data and concerns over cost-effectiveness.
It said it was unclear how much the drug would help the specific group of people for whom it was licensed - adults with relapsing-remitting multiple sclerosis (RRMS) who experienced at least one relapse a year despite being treated with beta interferon drugs.
Another group of patients suitable for the drug were those with rapidly evolving severe RRMS, who experience two or more disabling relapses regardless of their treatment.
Nice said Novartis had submitted data mainly looking at a subgroup of patients with the former type of MS.
Novartis also only submitted data comparing Gilenya with a placebo and with a type of beta interferon not believed to be widely prescribed on the NHS, according to Nice.
Professor Carole Longson, director of the health technology evaluation centre at Nice, said: "While it's important that people with multiple sclerosis have treatment options, Nice has to ensure that the NHS provides treatments that bring benefits that are value for money.
"Unfortunately our independent committee wasn't given sufficient evidence to show that fingolimod could reduce relapses considerably better than the other treatments currently being used.
"Based on the available clinical evidence and economic analysis, our independent committee concluded that fingolimod would not be effective good use of NHS resources."
Simon Gillespie, chief executive of the MS Society, said: "This is disappointing news for people with MS and it will leave some people with no effective treatment option.
"Access to MS treatments in the UK is very poor - in fact people with MS would be better off living almost anywhere else in Europe, and this decision will only deepen that inequality.
"We're concerned at how this decision has been reached and now strongly encourage Nice and Novartis to work together to look at how the treatment can be better re-considered and evaluated."
Novartis said Nice had suggested best supportive care (no active treatment at all) as the appropriate comparator for Gilenya.
But it said this did not reflect current clinical practice in the UK according to neurologists.
A statement said: "Novartis believes that comparing fingolimod to best supportive care will unfairly restrict access to fingolimod, as well as any future new treatments.
"It will be very difficult for any new therapy to demonstrate cost effectiveness against best supportive care.
"This approach is likely to restrict new treatment options in the UK to symptom management medicines only, which could result in continued relapses."
MS has traditionally been treated with injectable drugs. Around 100,000 people in the UK have MS.
Swedish stars ask fans for £195 pledges on crowd-funding website
voicesJust when you thought you could find a man, get married, and have a baby by the age of 35... it turns out you’re too late, says Grace Dent
sportNapoli 2 Arsenal 0: Gunners must now face either Real Madrid, PSG, Bayern Munich, Atletico Madrid or Barcelona in knock-out stages
musicAs Mariah Carey and Noddy Holder rake in the royalties from their classics, why there hasn't been a decent festive hit for 20 years?
theatreAuthor Daniel Rosenthal recalls the mishaps that almost brought the curtain down on the likes of John Gielgud and Diana Rigg
filmFilm producers sue Warner Bros for $75m over Hobbit films
lifeAs the Royal Mail plans to phase out deliveries on two wheels, it's no wonder posties are in a spin
musicThe 21-year-old beat Ella Eyre and Chlöe Howl to win the honour
lifeFull of the joys and want to help your fellow man? December isn't the time to do it
techLuke Blackall reports on precision engineered prams and babygros that monitor your child 24-7
Life & Style blogs
YouTube: Top trending videos of 2013 - including Tom Daley and Peppa Pig
Chinese scientists 'increasingly confident' about invisibility cloak after making a cat disappear
GTA 5 update: Content Creator released, online heists and story mode updates coming soon
The rise of goo-goo gadgets: Hey baby, nice wheels!
Pirate Bay sets sail for Ascension Island after SX domain name seized by authorities
- 1 Nelson Mandela memorial: ‘Bogus’ interpreter made mockery of Barack Obama’s tribute
- 2 It’s shameful that our universities have accepted gender segregation under pressure from the most oppressive religious fanatics
- 3 John McAfee's $100 'anti-NSA' device: 'this is coming and cannot be stopped'
- 4 Is Facebook making us forget? Study shows that taking pictures ruin memories
- 5 Australia incest case: Filthy and severely deformed children found in remote farming community after generations of inbreeding
- < Previous
- Next >
£77099.84 - £96375.26 per annum + Bonus + Benefits : Harrington Starr: My clie...
£45000 - £60000 per annum + Bonus and Package: Harrington Starr: Trading appli...
£35000 - £38000 per annum + Benefits: Harrington Starr: C# .NET Developer (Win...
£60000 - £70000 per annum + Benefits: Harrington Starr: Senior QA Engineer Tes...